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Abstract
Background: Anorectal malignant melanomas (ARMM) are rare tumors, characterized by an early lymphatic spread
and distant metastasis, resulting in an extremely poor overall survival. The objective of this study was to determine
the pattern of regional lymph node metastasis (LNM) by computed tomography (CT) and 18F-FDG-PET/CT in
patients undergoing abdominoperineal resection (APR) and its impact on oncologic outcome.
Methods: A retrospective analysis of six consecutive patients who underwent APR due to primary ARMM was
performed. Patients were staged by CT and PET/CT.
Results: Four out of six patients had preoperative LNM involvement (two patients inguinal and perirectal, one
iliacal, one perirectal), with two of them presenting with distant metastases additionally. Inguinal/iliacal LNM in two
patients as well as liver metastasis in one patient was seen in PET/CT and missed by CT. The three patients with
initial inguinal/iliacal LNM died during the observation period (overall survival: 10 (6–18) months). The three patients
without inguinal/iliacal LNM involvement are currently alive, one patient showing a slowly progressive disease since
5 years, and two patients are tumor-free since 8.5 and 1.5 years (the patients had initial perirectal LNM).
Conclusions: In ARMM, PET/CT is superior to CT in detection of LNM and distant metastasis. APR is possibly a
curative approach if the PET/CT shows exclusively perirectal LNM despite locally advanced tumor growth.
Keywords: Anal melanoma, Rectal melanoma, Anus neoplasms, Colorectal surgery, Abdominoperineal resection,
Computed tomography, PET
Background
Anorectal malignant melanomas (ARMM) are extremely
rare and aggressive tumors representing 0.05 % of all
malignant colorectal diseases and 0.5 to 4.6 % of all ano-
rectal malignancies [1–4]. Despite an improvement of la-
boratory tests, as well as diagnostic imaging modalities
and the development of multimodal therapy concepts in
oncology, the prognosis of ARMM remains extremely
poor. The median overall survival after diagnosis is spe-
cified to be between 8 and 19 months [5, 6]. Male gen-
der, perineural invasion, infiltration depth of the rectal
wall, lymph node metastasis (LNM), and distant metas-
tasis are associated with a poor overall survival in
ARMM [7–13]. LNM are detectable in more than 40 %
of cases when an infiltration of the submucosa has oc-
curred [9]. And, LNM is reported to be associated with
a near to 0–5-year disease-specific survival [8]. This can
be attributed to the fact that lymphatic spread in ARMM
results in distant metastasis to the lung and liver in up
to 90 % of cases [8, 12]. Until present, no patient has been
reported to have survived more than 5 years in case of dis-
tant metastasis [14]. So although it is published that LNM
in ARMM are associated with a poor overall survival, little
is known about lymphatic spread to the inguinal/iliac
lymph nodes or to the perirectal lymph nodes or to both
regions, and if surgery should be adapted. The few existing
data are inconsistent [15–17]. However, more than 10 dif-
ferent lymphatic pathways were described in the anal area
[18], and a simultaneous presence of perirectal and in-
guinal LNM seems to be rare [19]. 18F-FDG-PET/CT scan
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is established in staging and follow-up examination of cu-
taneous melanomas [20]. Data about 18F-FDG-PET/CT
in ARMM are sparse [21–26]. In general, the radical abdo-
minoperineal resection (APR) [14] and the dissection of
inguinal lymph nodes provide no survival benefit in
ARMM [2]. The few long-term survivors described, how-
ever, often underwent APR [3, 9, 27, 28].
The objective of this study was to determine the pattern
of inguinal/iliacal and perirectal lymph node metastasis by
18F-FDG-PET/CT or contrast-enhanced computed tom-
ography (CT) in patients undergoing abdominoperineal
resection and its impact on the oncologic outcome.
Methods
Patient group
A retrospective analysis of six consecutive patients who
underwent abdominoperineal resection due to primary
ARMM at the university hospital of Tuebingen between
2007 and 2014 was performed. The individual patients’
history, the pretreatment staging findings, and the radio-
logic findings are systematically listed in Tables 2 and 3.
Demographic, diagnostic, surgery-related, and histopatho-
logic parameters were examined using the clinic’s docu-
mentation system. The patients were investigated by
contrast-enhanced whole-body CT and additionally by
18F-FDG-PET/CT (five patients) before surgery. The
ARMM were categorized using a four-stage classification
taking into account the depth of tumor infiltration (stage I
and II), regional or lymphatic spread (stage III), and dis-
tant metastasis (stage IV) (Table 1 [14]). All patients were
followed-up closely after surgery for up to 8.5 years.
Imaging
Patient preparation: after fasting for 12 h to ensure opti-
mal glucose uptake during the examination, 350 MBq of
18F-FDG was injected intravenously. Patients were asked
to rest during the uptake time to keep muscular glucose
uptake on a low level. To facilitate the evaluation of the
intestinal wall, 1000 ml 2.5 % mannitol solution was ad-
ministered orally for intestinal distension. Before image
acquisition, 40 mg butlyscopolaminiumbromid was
injected intravenously to suppress intestinal motion,
thus improving visualization of the intestine and closely
surrounding structures and reducing misalignment of
PET and CT images.
Examination protocol
Due to the inclusion period of 7 years, patients were ex-
amined with a 16-slice whole-body PET/CT or with a
128-slice whole-body PET/CT (Hi-Rez Biograph 16/Bio-
graph 128, Siemens Health Care, Knoxville TE, USA).
Imaging techniques were comparable regarding image
acquisition and diagnostic results. The technical parame-
ters of the multidetector spiral CT and for PET have
already been published by our research group [29]. Each
examination consisted of a full diagnostic contrast-
enhanced multidetector CT image acquired in the porto-
venous phase after injection of 80–120 ml iopromide
(370 mg iodine/ml, flow rate 3 ml/s, Ultravist 370®,
Bayer, Leverkusen, Germany), adjusted according to the
patients’ body weight followed by a chaser of 40 ml sa-
line and a high-resolution three-dimensional LSO PET
covering 6–7 beds, depending on the patients’ size. The
attenuation correction of PET data was performed using
the contrast-enhanced CT images. PET image acquisi-
tion was started 1 h after 18F-FDG injection. CT images
were reconstructed in transversal and coronal slice
orientation with 5-mm slice thickness/5 mm increment
in the transversal plane and 3-mm slice thickness/2 mm
increment in the coronal plane, respectively.
Image analysis
Image fusion of PET and CT data and evaluation of the
separate CT and PET as well as fused PET/CT images were
performed on a dedicated PET/CT workstation (TrueD,
Siemens Health Care, Erlangen, Germany). Two experi-
enced readers (specialists in radiology and nuclear medi-
cine) evaluated CT and PET images separately, as well as
the fused PET/CT images. This was done in a consensus
mode for the presence of regional and distant metastases,
as well as the extent of the primary tumor at the initial
examination. For study purposes, a secondary analysis of
CT and PET as well as merged PET/CT images was per-
formed by a radiologist with 12 years of experience in on-
cologic imaging. To compare the diagnostic yield of CT
and PET/CT, contrast-enhanced CT images of the PET/
CT examination were assessed prior to reading the merged
PET/CT image series to prevent a bias arising from the
knowledge of the PET findings. Using CT data from the
PET/CT examination ensures comparable disease stage,
because acquisition took place at the same time.
Results
The median age of the total cohort was 66.5 (range 54–73)
years. Women were more often affected than men. All
ARMM were localized to the dentate line, and tumor
diameter varied between 0.4 and 11 cm at the time of
diagnosis. In three patients, ARMM were diagnosed by
biopsy and in the other three patients after performing
local excision. In two patients the ARMM were
Table 1 Staging classification of ARMM
Stage Tumor spread
I Local tumor spread without infiltration of the muscular layer
II Local tumor spread with infiltration of the muscular layer
III Regional tumor spread and/or positive lymph node metastasis
IV Disseminated tumor spread
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amelanotic. KIT, BRAF, or NRAS mutations were not de-
tectable in any patient. Serum levels of S100 protein was
just elevated in patients having synchronous distant me-
tastasis. Table 2 displays demographic data, tumor charac-
teristics including histopathology, immunostaining, and
mutation analysis as well as the therapy performed for
each patient separately.
As tabulated in Table 3, four out of six patients had pre-
operative LNM involvement with two of them presenting
with distant metastases additionally. In two patients, com-
bined inguinal and perirectal LNM were determined. One
patient had perirectal LNM exclusively and in another pa-
tient a solitary iliac LNM could be shown. During pre-
operative staging, inguinal/iliacal LNM in two patients as
well as liver metastasis in one patient were seen in PET/
CT and missed by CT. Also, when regarding metachro-
nous metastases in the follow-up examination after sur-
gery, in one patient, focally increased glucose uptake in
the liver without correlating findings in CT were regis-
tered. On the other hand, in one patient, lymphonodular
involvement was overestimated by CT which might arise
from reactive lymph node enlargement without pathologic
metabolic activity characteristic for melanoma metastases.
Figure 1 shows examinations performed by CT and PET/
CT where an iliac LNM could be diagnosed by PET/CT,
but was not considered as suspect for LNM on CT im-
aging, and in Fig. 2, hepatic metastases were evident in the
PET/CT examination, but not in the CT scan.
Abdominoperineal resection was performed in five pa-
tients within 1 to 3 months after diagnosis and in one pa-
tient with a 13-month delay. In this patient, previous local
excision was performed due to the initial assessment as a
palliative situation in case of iliacal LNM involvement.
Three patients underwent APR in palliative intention. Five
patients received an adjuvant or additive therapy. In one
patient, hepatic toxicity was detected early, so ipilimumab
was canceled after one cycle. Only one patient underwent
adjuvant radiotherapy (inguinal and pelvic).
Three patients died during the observation period (me-
dian survival: 10 (range 6–18) months). All three patients
had synchronous inguinal or iliacal LNM. The other three
patients did not have synchronous inguinal or iliacal LNM;
one of them had perirectal LNM exclusively. Two patients
are tumor-free since 8.5 and 1.5 years, including the patient
who had synchronous perirectal LNM. The other patient
shows a slowly progressive disease since 5 years. Nineteen
months following extralevator abdominoperineal resection
(ELAPR), a solitary pulmonary metastasis was diagnosed
and resected. However, shortly afterwards, again, pulmon-
ary metastases and mediastinal LNM were detected.
Discussion
Despite a rapid development of diagnostic tools and ad-
vance in multimodal cancer therapy, the overall survival
of ARMM has not substantially improved in the past de-
cades. The lack of diagnostic and treatment standards is
based on the rarity of this condition. An extended review
of the literature, published in 2013 by our working
group summarized the reported cases of ARMM to a
total of 2650 [14]. In accordance to our patient popula-
tion, the literature shows a high rate of LNM and distant
metastases at initial diagnosis of ARMM and frequent
metachronous metastases after a few months, which is
associated with the poor overall survival [14]. In general,
the overall survival cannot be improved by a radical sur-
gical approach [14, 19, 30–32]. However, in the pre-
sented collective as well as in published studies, few
long-term survivors seem to benefit from an abdomino-
perineal resection [3, 9, 27]. As far as no curative drug
therapy is available, the identification of patients who
could benefit from radical surgery (APR/ELAPR) is of
paramount importance. For this, a diagnostic and treat-
ment algorithm has been proposed [14]. Besides the in-
dividual tumor biology and perineural invasion, the
lymphatic spread seems to have a key role affecting the
poor overall survival [14, 33]. Systematic studies on the
clinical relevance of LNM in ARMM are missing. And,
the few existing data which try to structure the issue are
quite inhomogeneous [19]. Analogous to the radical
APR with total mesorectal excision, the groin lymph
node dissection seems to have no influence on overall
survival as well [2]. The reason for this might be found
in the complex lymphatic drainage system of the anal re-
gion [27]. Up to now, more than 10 different lymphatic
paths were found in the anal area [18]. Using a double-
tracer technique (radiotracer and dye), Iddings et al.
showed that all patients with ARMM drained to the in-
guinal node basin and even often to both sides [17]. This
contrasts with historical studies on cadavers in which
submucosal injections of quicksilver at the level of the
dentate line shows a drainage to perirectal lymph nodes
in 90–93 % [16]. Perez et al. published a rare simultan-
eous presence of perirectal and inguinal LNM [19]. Be-
cause of limitation of APR with total mesorectal excision
on resection of perirectal LNM, only patients without
LNM or with an exclusively perirectal lymphatic spread
could benefit from radical surgery in curative intent. In-
formation about non-invasive examination procedures
such as the PET/CT in preoperative staging of ARMM,
especially in detecting of lymphatic metastasis, is rare.
Up to now, only a few case reports [21–25] and a case
series of five patients [26] have been published. Several
studies gave evidence that 18F-FDG-PET/CT provides
superior diagnostic accuracy for the detection of metasta-
ses in malignant melanoma [20, 34–38] and in detecting
recurrent colorectal carcinoma [39] compared to contrast-
enhanced CT. The observations in our patient population
also suggest that 18F-FDG-PET/CT is superior to the
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Table 2 Patient and therapy parameter, tumor characteristics, and follow-up data
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years) 66 63 54 67 73 68
Gender Male Male Female Female Female Female
Diagnosis before abdominoperineal
resection
S100 protein in serum
(normal range < 0.1 μg/l)
0.079 0.301 0.049 0.199 0.039 0.050
Preoperative biopsy – Yes – Yes – Yes




APR ELAPR ELAPR ELAPR lap. ELAPR lap. ELAPR
Intention for abdominoperineal
resection
Curative Palliative Curative Palliative Palliative Curative
Time interval between diagnosis
and APR (months)
3 1 3 2 13 2
Adjuvant/additive therapy – DTIC 1. Ipilimumab DTIC 1. Radiation Ipilimumab (1 cycle)




Tumor stage I IV II IV III III




On and above DL
(multifocal)
DL DL Above DL
Tumor diameter (cm) 0.9 11 0.5 + 0.4 + 0.4 10.5 <1 10,9
Depth of infiltration (mm) <3 15 4 All layers 3 All layers
Negative resection margin (R0) Yes Yes (<1 mm) Yes Yes Yes (marginal) Yes
Amelanotic melanoma Yes No No Yes No No
S100 protein – – – Positive – Positive
Melan-A – Positive – Positive – Positive
Mutation analysis
KIT – Wild–type Wild–type Wild–type Wild–type Wild–type
BRAF – – Wild–type Wild–type Wild–type Wild–type
NRAS – – Wild–type Wild–type – Wild–type
Follow up (months) 102 6 60 10 18 18
Local recurrence No Yes No No Yes No
Time interval to abdominoperineal
resection (months)
– 1 – – 3 –
Metachronous lymph node metastasis No ns Yes Yes Yes No
Mediastinum – – Yes Yes – –
Perirectal – – – – yes –
Time interval to abdominoperineal
resection (months)
– – 42 3 5 –
Metachronous distant metastasis No ns Yes Yes Yes No
Lung/pleura – ns Yes – Yes No
Liver – – No Yes Yes No
Peritoneum – ns No No Yes No
Bone – ns No No Yes No
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contrast-enhanced CT for detection of LNM and distant
metastasis in some cases of ARMM. Altogether, in the
preoperative staging, combined with the findings done
during the follow up investigations, PET/CT identified
distant metastases in two patients in the liver as well as
metastatic lymph node involvement in two patients, which
were all missed by contrast-enhanced CT. All LNM and
distant metastasis described in PET/CT could be verified
by histopathology (perirectal LNM) or have been con-
firmed in the short-term clinical course. On the other
hand, in one patient lymphonodular involvement was
overestimated by CT which might arise from reactive
lymph node enlargement without pathologic metabolic ac-
tivity characteristic for melanoma metastases. Although
no statistical conclusions could be derived from these re-
sults due to the small number of patients, this supports
the assumption that PET/CT contributes to improved
diagnostic certainty in ARMM. Our observation confirms
the descriptions of the only recently published collective,
in which five patients with ARMM were examined pre-
operatively by PET/CT and by contrast-enhanced CT [26].
With regard to the primary tumor, PET/CT is of special
interest. Tumor manifestations of the enteric wall tend to
evade detection by morphologic assessment such as
contrast-enhanced CT as lesions might be masked by stool
or peristaltic muscle contraction or no circumscript tumor
could be identified due to infiltrative growth. Especially
after prior surgery, differentiation between scar tissue and
new or recurring tumor is challenging. These patients will
benefit from PET/CT to estimate tumor extent when con-
sidering surgical resection, especially in entities with high
glucose consumption which usually is the case in malig-
nant melanoma [29].
In our patient population, APR was performed in pallia-
tive intention in three patients. In each patient, inguinal or
iliac LNM and distant metastases were evident. None of
the three patients survived longer than 18 months after
surgery. In contrast, during the observation period, three
other patients survived, two of them without tumor recur-
rence. Interestingly, all three patients did not have any ini-
tial inguinal or iliac LNM, however, one patient had
perirectal LNM exclusively. Already published data and
the results in our patient population suggest that patients
with initial inguinal/iliac LNM have no curative surgical
option. Patients with perirectal LNM exclusively could
benefit from curative APR even in the long term. Thus,
the individual lymphatic anatomy of the anorectal region
could be a decisive prognostic factor in ARMM and
should be taken into account for patient selection for APR
until no other valid data are available. Therefore, the 18F-
FDG-PET/CT appears to be a useful tool for decision-
making. In the three patients, an extralevator abdomino-
perineal resection was performed with palliative intention.
The extent of resection was chosen analogous to the re-
section standards for very low rectal cancer in our univer-
sity hospital. Due to the potentially higher morbidity of
the extralevator abdominoperineal resection, the radical-
ness of surgery should be reduced to local tumor control
in a palliative situation.
Due to the rarity of ARMM, no randomized controlled
trials can be expected in the next few decades, particu-
larly not answering all relevant questions concerning
diagnosis and therapy of ARMM. Therefore, all patients
with ARMM should be treated in specialized centers for
recording data prospectively and to publish further case
series. For a comparability of the data, we suggest a stan-
dardized recording, which is proposed by our working
group [14].
Conclusions
18F-FDG-PET/CT is superior to contrast-enhanced CT
in staging of ARMM. LNM as well as distant metastasis,
which might be missed by CT, was detected by PET/CT.
Despite sparse data and a significantly higher cost
Table 2 Patient and therapy parameter, tumor characteristics, and follow-up data (Continued)
Soft tissue – ns No No Yes No
Brain – ns No No Yes No
Time interval to abdominoperineal
resection (months)
– – 21 3 12 –
Health status at follow-up time
interval to abdominoperineal
resection (months)
Disease-free Dead 6 Slowly progressive
disease
Dead 10 Dead 18 Disease-free
Before surgery, elevated serum levels of S-100 were measured only in patients with distant metastasis (stage IV). In all patients, the tumor origin was on or slightly
above the dentate line. In patient 2, the tumor invades the anal canal. And, in patient 3, the ARMM was found at several localizations around the dentate line.
During the first surgery, clear resection margins (R0) were achieved in all six patients. In patients 2 and 5, the resection margins were just barely R0. In patient 5,
primarily, a local excision was performed. While in this patient multiple local recurrences were removed by local procedures over a time period of several months,
also an LNM in the mesorectum was detected in the course. Consequently, laparoscopic extralevator abdominoperineal resection was carried out for local control.
However, at this time, the tumor mass was not removable in total (R1). Patient 3 shows an atypical course of ARMM with a slowly progressive disease for more
than 5 years
APR abdominoperineal resection, ELAPR extralevator abdominoperineal resection, lap. ELAPR laparoscopic extralevator abdominoperineal resection, DTIC
dacarbacin, DL dentate line, ns not specified
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Table 3 Preoperative radiological staging and histopathological verification of lymph node metastasis in the mesorectum
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Occurrence Detected in Occurrence Detected in Occurrence Detected in Occurrence Detected in Occurrence Detected in Occurrence Detected in
CT PET/CT CT PET/CT CT PET/CT CT PET/CT CT PET/CT CT PET/CT
Synchronous LNM No Yes No Yes Yes Yes
Perirectal – Yes X X – Yes X X – Yes X X
Inguinal right – Yes Ø X – – – –
Iliacal right – – – – Yes Ø X –
Inguinal left – Yes X X – Yes X X – –
Iliacal left – – – – – –
LNM in histopathology No Yes No Yes Yes Yes
Perirectal (LNM/resLN) 0/12 13/33 0/14 1/3 (3/21)a 1/5
Synchronous distant
metastasis
No Yes No Yes No No
Lung/pleura – – – Yes X X – –
Liver – Yes Ø X – – – –
Detection of perirectal, inguinal, and iliacal lymph node metastases, as well as lung and liver metastases as depicted by contrast-enhanced CT and by 18F-FDG-PET/CT. Additionally, histopathologically verified lymph
node metastases in relation to total count of examined lymph nodes are listed
CT computed tomography, PET/CT 18F-FDG PET/CT, LNM lymph node metastasis, resLN total count of resected lymph nodes













burden compared to conventional diagnostics, PET/CT
should be an obligatory part of the preoperative staging
in ARMM. Patients, in which PET/CT shows perirectal
LNM solely, could potentially benefit from curative
abdominoperineal resection despite locally advanced
tumor growth. Also, for staging in ARMM, there will be
no randomized controlled data available in the foresee-
able future. So, further extended case series should be
published based on standardized collected data on PET/
CT in ARMM.
Fig. 1 CT and PET/CT for pelvic imaging in anorectal malignant melanoma. A seventy-three-year-old female patient (patient 5) with a small iliacal
lymph node metastasis on the right side (dashed arrow) and a relapse from anal melanoma. Contrast-enhanced CT reveals a small lymph node
beside the right internal iliac artery of round configuration with uncertain dignity (a). PET/CT, however, indicates increased FDG uptake suspicious
for metastasis (b). The follow up examination 9 months later provides clear evidence of progressive lymphatic metastasis on the right iliac side
(arrow) on CT (c) and PET/CT (d) images. The lymph node is enlarged with a destroyed anatomical structure and increased glucose uptake. PET/
CT enabled detection of lymph node metastasis in an early state
Fig. 2 CT and PET/CT for hepatic imaging in anorectal malignant melanoma. A sixty-three-year-old male patient (patient 2) with a large anorectal
melanoma, inguinal lymphatic metastases on both sides, and distant metastases. PET/CT depicts two hepatic metastases in segment six (b) and
eight (not in the picture) without any corresponding findings on contrast-enhanced CT (a). Staging based on CT underestimated tumor stage by
missing the distant metastatic spread completely in this patient
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